Ngenla 24 mg Somatrogon Information
Ngenla 24 mg is identified in this listing as a somatrogon product reference. Based on the information provided, it is presented as a long-acting growth hormone analogue developed by Pfizer and associated with a pre-filled subcutaneous pen format. This page is written for neutral product identification and specification checking rather than treatment guidance.
The supplied information references Ngenla in 24 mg and 60 mg presentations and describes the 24 mg version specifically in relation to once-weekly administration in its approved context. As with any sensitive healthcare product listing, the most important checks are the exact product name, stated substance, listed strength and presentation shown on the original packaging. Where a listing includes summary text, it should be treated as supporting information only and verified against the manufacturer-labelled details.
Product Overview
Ngenla is described in the provided information as containing somatrogon-ghla and as being structurally modified in a way that extends its duration compared with traditional somatropin references. The listing also notes a pre-filled pen presentation for subcutaneous administration. For catalogue accuracy, the key distinction on this page is the stated 24 mg strength and the somatrogon identification.
The source text also mentions comparative growth figures of 10.1 cm per year and 9.8 cm per year from clinical study context. These figures are retained here only as part of the supplied reference content and not as a claim about expected outcomes for any individual case.
What to Check on the Listing
- Product name: Ngenla
- Listed substance: Somatrogon or somatrogon-ghla
- Stated strength: 24 mg
- Presentation noted in the supplied information: pre-filled subcutaneous pen
- Manufacturer named in the supplied information: Pfizer
If comparing different listings, it is useful to distinguish strength, presentation format and any manufacturer wording shown on the outer packaging. This helps avoid confusion between similarly named products or different strengths within the same range.
Technical Information
| Product name | Ngenla |
|---|---|
| Listed substance | Somatrogon-ghla |
| Stated strength | 24 mg |
| Product type | Long-acting growth hormone analogue |
| Presentation mentioned | Pre-filled subcutaneous pen |
| Manufacturer mentioned | Pfizer |
| Other strengths mentioned in source text | 60 mg |
| Reference measurements in supplied text | 10.1 cm/year and 9.8 cm/year |
Handling and Packaging Notes
Retain the packaging for verification and check that the printed product name, strength and presentation match the listing. Store according to the information printed on the original packaging. If any detail on the pack differs from the listing reference, the product information should be checked carefully before relying on it for identification.
Frequently Asked Questions
- What is Ngenla 24 mg identified as in this listing?
- It is identified as Ngenla with the listed substance somatrogon-ghla and a stated strength of 24 mg.
- What presentation is mentioned in the provided information?
- The supplied text refers to a pre-filled subcutaneous pen presentation.
- Is a manufacturer named for Ngenla in the source content?
- Yes. The provided information names Pfizer.
- Does this page provide dosage or personal treatment guidance?
- No. This page is limited to neutral product information and specification reference only.
- Are other strengths mentioned alongside Ngenla 24 mg?
- Yes. The source text also mentions a 60 mg presentation.
- What should be checked first when verifying this product?
- Check the exact product name, listed substance, stated 24 mg strength and the presentation shown on the original packaging.